DSM-Firmenich AG (DSFIR) Earnings Call Transcripts
DSM-Firmenich AG's Latest Earnings Call - Q1 FY2026
DSM-Firmenich AG reported its Q1 2026 earnings, highlighting a 4% volume-driven organic sales growth, with a significant impact from FX and M&A activities. The company maintained its full-year guidance of 2% to 4% organic sales growth, 20% EBITDA quality, and 11% to 12% cash conversion. The announcement of a dual listing on the SIX Swiss Exchange could potentially increase investor interest and liquidity. Despite macroeconomic volatility, the company showed resilience, particularly in its Perfumery & Beauty segment.
Reported metrics
| Metric | Value |
|---|---|
| Organic Sales Growth | 4% (inline) |
| EBITDA Margin | 19% (inline) |
| Perfumery & Beauty Volume Growth | 8% (beat) |
| FX Impact | -6% (negative) |
Guidance from management
DSM-Firmenich maintained its full-year 2026 guidance of 2% to 4% organic sales growth, 20% EBITDA quality, and 11% to 12% cash conversion. Management expressed confidence in achieving these targets despite macroeconomic challenges.
What management said
Good morning, and thank you for joining today's call. I'm sitting here with Dimitri de Vreeze, our CEO; and Ralf Schmeitz, our CFO. We published this morning our trading update for the first quarter, which you can find on our website. Here, you can also find our disclaimers about forward-looking statements. Following Dimitri's and Ralf's opening comments, we will open the line for questions as usual. Important to rem...
And if I can add to that, keep in mind also the comps in both TTH and agency when we saw a very strong Q1 last year with 7% and 6% growth with a strong Dietary Supplements that we called out at the time. That's to be seen in that light as well.
What analysts pressed on
Analysts expressed concerns about the impact of advance orders on future quarters and the ability to manage cost pressures from energy and logistics. There were also questions about the sustainability of growth in the Perfumery & Beauty segment and the impact of FX on margins.
Main topics on the call
- Volume-Driven Growth — DSM-Firmenich reported a 4% volume-driven organic sales growth, with significant contributions from Perfumery & Beauty, which saw an 8% increase in volumes. Management stated, 'We delivered like-for-like sales growth, wh...
- FX and M&A Impact — The reported sales were negatively impacted by a 6% adverse FX effect and a 1% impact from M&A activities, reflecting the sale of the Agro Ingredients business. The company expects these impacts to phase out over the yea...
- Perfumery & Beauty Performance — The Perfumery & Beauty segment showed strong performance with an 8% volume increase, driven by Fine Fragrance's double-digit growth. Management attributed this to a strong brief pipeline and new wins.
- Dual Listing Announcement — DSM-Firmenich announced a dual listing on the SIX Swiss Exchange, aiming to access a broader investor base and increase stock liquidity. Management emphasized the strategic importance of this move.
Read the full DSM-Firmenich AG transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About DSM-Firmenich AG
DSM-Firmenich AG (DSFIR) is a publicly listed company in the Chemicals industry, within the Materials sector. It trades on ENXTAM and is based in NL. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 37 calls on record spanning February 13, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 37 DSM-Firmenich AG earnings call transcripts on record, spanning February 13, 2020 to July 30, 2026. Based on this history, DSM-Firmenich AG reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.